FDA Clears Safety Test To Screen Tysabri Patients

Salon Staff
January 21, 2012 2:27AM (UTC)

WASHINGTON (AP) — The Food and Drug Administration says it has approved a new diagnostic test to help identify patients who have an increased risk of developing a rare brain infection while taking Biogen Idec's multiple sclerosis drug Tysabri.

Tysabri is one of a handful of drugs used to control multiple sclerosis, a debilitating disease in which the body attacks its own nervous system. Prescribing of the drug has been tightly controlled by the FDA because of a rare side effect that causes fatal inflammation of the brain.


The newly approved Stratify JCV test is designed to detect a common virus that increases patients' chances of developing the brain infection. The virus is harmless in most patients, but can become dangerous in patients taking immune system-suppressing drugs like Tysabri.

Salon Staff

MORE FROM Salon Staff


Read Now, Pay Later - no upfront
registration for 1-Hour Access

Click Here
7-Day Access and Monthly
Subscriptions also available
No tracking or personal data collection
beyond name and email address


Fearless journalism
in your inbox every day

Sign up for our free newsletter

• • •